Metabolic syndrome and breast cancer: An overview

Journal of B.U.ON.

Volumn 17, Issue 2, 2012, Pages 223-229

  Gezgen, G ^a   Roach, E C ^a   Kizilarslanoglu, M C ^a   Petekkaya, I ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Metabolic syndrome; Predictive; Prognosis

Indexed keywords

ADIPOCYTOKINE; CD36 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MESSENGER RNA; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPRANOLOL; TROGLITAZONE;

BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DYSLIPIDEMIA; FATTY ACID SYNTHESIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT;

BREAST NEOPLASMS; FEMALE; HUMANS; METABOLIC SYNDROME X; PROGNOSIS;

EID: 84863614031     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30. (Pubitemid 40310185)
2. Ozmen V. Breast cancer in the World and Turkey. J Breast Health 2008; 4: 6-12.
3. Gundogan K, Bayram F, Capak M et al. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab Syndr Relat Disord 2009; 7: 427-434.
4. Oguz A, Sagun G, Uzunlulu M et al. Frequency of abdominal obesity and metabolic syndrome in healthcare workers and their awareness levels about these entities. Turk Kardiyol Dern Ars 2008; 36: 302-309 (in Turkish with Engl abstr).
5. Kabat GC, Kim M, Rowan T et al. A Longitudinal Study of the Metabolic Syndrome and Risk of Postmenopausal Breast Cancer. Epidemiol Biomarkers Prev 2009; 18: 2046-2053.
6. Pasanisi P, Berrino F, De Petris M et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006; 119: 236-238.
7. Agnoli C, Berrino F, Abagnato CA et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis 2010; 20: 41-48.
8. Healy LA, Ryan AM, Carroll P et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 2010; 22: 281-288.
9. Coughlin SS, Calle EE, Teras LR et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167. (Pubitemid 38747263)
10. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: A review of the current evidence. Am J Clin Nutr 2007; 86: s823-s835.
11. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007; 121: 856-862. (Pubitemid 47106217)
12. Peairs KS, Barone BB, Snyder CF et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29: 40-46.
13. Yancik R, Wesley MN, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-892. (Pubitemid 32171549)
14. Srokowski P, Fang S, Hortobagyi GN et al. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009; 27: 2170-2176.
15. Fleming ST, Pursley HG, Newman B et al. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care 2005; 43: 132-141.
16. Du W, Simon MS. Racial disparities in treatment and survival of women with stage I-III breast cancer at a large academic medical center in metropolitan Detroit. Breast Cancer Res Treat 2005; 91: 243-248. (Pubitemid 40896570)
17. Fresno Vara JA, Casado E, de Castro J et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
18. Wolf I, Seger R. The mitogen-activated protein kinase signaling cascade: from bench to bedside. Isr Med Assoc J 2002; 4: 641-647. (Pubitemid 34873779)
19. Lai A, Sarcevic B, Prall OW, Sutherland RL. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem 2001; 276: 25823-25833.
20. Papa V, Pezzino V, Costantino A et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990; 86: 1503-1511.
21. Mathieu MC, Clark GM, Allred DC et al. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997; 109: 565-567.
22. Goodwin PJ, Ennis M, Pritchard KI et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20: 42-45.
23. Del Giudice ME, Fantus IG, Ezzat S et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998; 47: 111-120. (Pubitemid 28046082)
24. Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: Findings from the British Women's Heart and Health Study. Cancer Causes Control 2004; 15: 267-275. (Pubitemid 38988035)
25. Jernstrom H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: The Rancho Bernardo Study. J Womens Health Gend Based Med 1999; 8: 1265-1272. (Pubitemid 30042477)
26. Mink PJ, Shahar E, Rosamond WD et al. Serum insulin and glucose levels and breast cancer incidence: The atherosclerosis risk in communities study. Am J Epidemiol 2002; 156: 349-352. (Pubitemid 34858003)
27. Muti P, Quattrin T, Grant B J et al. Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1361-1368. (Pubitemid 35340370)
28. Irwin ML, Duggan G, Wang CY et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 2011; 29: 47-53.
29. Bruning PF, Bonfrer JM, van Noord PA et al. Insulin resistance and breast-cancer risk. Int J Cancer 1992; 52: 511-521.
30. Yang G, Lu G, Jin F et al. Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 1207-1211. (Pubitemid 33064310)
31. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001; 8: 197-209. (Pubitemid 32947642)
32. Renehan AG, Zwahlen M, Minder C et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353. (Pubitemid 38529873)
33. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S et al. If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J Clin Oncol 2009; 27: e207-e209.
34. Bosco JL, Antonsen S, Sorensen HT et al. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011; 20: 101-111.
35. Bodmer M, Meier C, Krahenbuhl S et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33: 1304-1330.
36. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
37. Belda-Iniesta C, Pernia O, Simo R. Metformin: a new option in cancer treatment. Clin Transl Oncol 2011; 13: 363-367.
38. Jiang WG, Douglas-Jones A, Mansel RE. Expression of peroxisome proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1 in human breast cancer correlates with clinical outcomes. Int J Cancer 2003; 106: 752-757. (Pubitemid 36993400)
39. Burstein HJ, Demetri GD, Mueller E et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79: 391-397. (Pubitemid 36750946)
40. Park BH, Lee SB, Stolz DB et al. Synergistic Interactions between Heregulin and Peroxisome Proliferator-activated Receptor-{gamma} (PPAR{gamma}) Agonist in Breast Cancer Cells. J Biol Chem 2011; 286: 20087-20099.
41. Wilson C. Diabetes: Long-term use of insulin glargine might increase the risk of breast cancer. Nat Rev Endocrinol 2011 Jun 28. doi: 10.1038/nrendo.2011. 112.
42. Wolf I, Sadetzki S, Catane R. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6: 103-111. (Pubitemid 40197704)
43. Ursin G, Longnecker MP, Haile RW et al. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology 1995; 6: 137-141.
44. Lahmann PH, Hoffmann K, Allen N et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004; 111: 762-771. (Pubitemid 39062901)
45. Yumuk PF, Dane F, Yumuk VD et al. Impact of body mass index on cancer development. JBUON 2008; 13: 55-59. (Pubitemid 351460876)
46. Maiti B, Kundranda MN, Spiro TP et al. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 2010; 121: 479-483.
47. Pichard C, Plu-Bureau G, Neves ECM et al. Insulin resistance, obesity and breast cancer risk. Maturitas 2008; 60: 19-30.
48. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011; 103: 250-263.
49. Khaidakov M, Mitra S, Kang BY et al. Oxidized LDL Receptor 1 (OLR1) as a Possible Link between Obesity, Dyslipidemia and Cancer. PLoS One 2011; 6: e20277.
50. Sonmez B, Seker M, Bilici A et al. Is there any correlation among adiponectin levels in serum, tumor tissue and normal tissue of the same patients with breast cancer? J BUON 2011; 16: 227-232.
51. Carroll PA, Healy L, Lysaght J et al. Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer. Mo Carcinog 2011; 50: 643-651.
52. Peeters PH, van Noord PA, Hoes AW et al. Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort). Diagnostic investigation into mammarian cancer. J Hypertens 2000; 18: 249-254. (Pubitemid 30142839)
53. Lindgren A, Pukkala E, Tuomilehto J, Nissinen A. Incidence of breast cancer among postmenopausal, hypertensive women. Int J Cancer 2007; 121: 641-644. (Pubitemid 46986498)
54. Braithwaite D, Tammemagi CM, Moore DH et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 2009; 124: 1213-1219.
55. Largent JA, McEligot AJ, Ziogas A et al. Hypertension, diuretics and breast cancer risk. J Hum Hypertens 2006; 20: 727-732. (Pubitemid 44430670)
56. Li CI, Malone KE, Weiss NS et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women aged 65-79 years. Cancer 2003; 98: 1504-1513. (Pubitemid 37151507)
57. Melhem-Bertrandt A, Chavez-McGregor M, Lei X et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2645-2652.
58. Sloan EK, Priceman SJ, Cox BF et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70: 7042-7052.
59. Terry MB, Petrin M, Salafia CM et al. Preeclampsia, Pregnancy-related Hypertension, and Breast Cancer Risk. Am J Epidemiol 2007; 165: 1007-1014. (Pubitemid 46598830)
60. Fiorenza AMBA, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000; 30: 141-145. (Pubitemid 32151973)
61. Dilman VM, Berstein LM, Ostroumova MN, Tsyrlina YV, Ag G. Peculiarities of hyperlipidaemia in tumour patients. Br J Cancer 1981; 43: 637-643. (Pubitemid 11111252)
62. Kumar K, Sachdanandam P, Arivazhagan R. Studies on the changes in plasma lipids and lipoproteins in patients with benign and malignant breast cancer. Biochemistry Intern 1991; 23: 581-589.
63. Hoyer AP, Engholm G. Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women. Cancer Causes Control 1992; 3: 403-408.
64. Ferraroni M, Gerber M, Decarli A et al. HDL-Cholesterol and Breast Cancer: A Joint Study in Northern Italy and Southern France. Int J Epidemiol 1993; 22: 772-780. (Pubitemid 23331085)
65. Gaard M, Tretli S, Urdaul P. Risk of Breast Cancer in Relation to Blood Lipids: A Prospective Study of 31,209 Norwegian Women. Cancer Causes Control 1994; 5: 501-509. (Pubitemid 24335712)
66. Kokoglu E, Karaarslan I, Karaarslan HM. Alterations of serum lipids and lipoproteins in breast cancer. Cancer Lett 1994; 82: 175-178. (Pubitemid 24231982)
67. Moorman P, Hulka B, Hiatt R et al. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 1998; 7: 483-488. (Pubitemid 28354111)
68. Furberg AS, Veierod MB, Wilsgaard T et al. Serum High-Density Lipoprotein Cholesterol, Metabolic Profile, and Breast Cancer Risk. J Natl Cancer Inst 2004; 96: 1152-1160. (Pubitemid 39207051)
69. Owiredu WK, Donkor S, Addai BW Serum lipid profile of breast cancer patients. Pak J Biol Sci 2009; 12: 332-338.
70. Kucharska-Newton AM, Rosamond WD et al. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008; 18: 671-677.
71. Kim Y, Park SK, Han W et al. Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea. Cancer Epidemiol Biomarkers Prev 2009; 18: 508-515.
72. Irwin ME, Mueller KL, Bohin N et al. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2011; 226: 2316-2328.
73. Kuemmerle NB, Rysman E, Lombardo PS et al. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther 2011; 10: 427-436.
74. He L, Lu Y, Wang P et al. Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers. BMC Cancer 2010; 10: 601.
75. Agnoli C, Berrino F, Abagnato CA et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010; 20: 41-48.
76. Bjorge T, Lukanova A, Jonsson H et al. Metabolic syndrome and breast cancer in the Me-Can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010; 19: 1737-1745.
77. Kabat GC, Kim M, Chlebowski RT et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2046-2053.
78. Capasso I, Esposito E, Pentimalli F et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther 2011; 10: 1240-1243.
79. Rosato V, Bosetti C, Talamini R. Metabolic syndrome and the risk of breast cancer in postmenopausal women Ann Oncol 2011 May 5 [Epub ahead of print].
80. Beaulieu LM, Whitley BR, Wiesner TF. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays 2007; 29: 1029-1038. (Pubitemid 47522843)
81. Jevtic M, Velicki R, Popovic M. Dietary influence on breast cancer. J BUON 2010; 15: 455-461.